273 related articles for article (PubMed ID: 26490423)
41. Targeting the nucleolus for cancer intervention.
Quin JE; Devlin JR; Cameron D; Hannan KM; Pearson RB; Hannan RD
Biochim Biophys Acta; 2014 Jun; 1842(6):802-16. PubMed ID: 24389329
[TBL] [Abstract][Full Text] [Related]
42. Activation of the tumor suppressor p53 upon impairment of ribosome biogenesis.
Bursac S; Brdovcak MC; Donati G; Volarevic S
Biochim Biophys Acta; 2014 Jun; 1842(6):817-30. PubMed ID: 24514102
[TBL] [Abstract][Full Text] [Related]
43. AID and RAG1 do not contribute to lymphomagenesis in Emu c-myc transgenic mice.
Nepal RM; Zaheen A; Basit W; Li L; Berger SA; Martin A
Oncogene; 2008 Aug; 27(34):4752-6. PubMed ID: 18408759
[TBL] [Abstract][Full Text] [Related]
44. Direct relationship between the level of p53 stabilization induced by rRNA synthesis-inhibiting drugs and the cell ribosome biogenesis rate.
Scala F; Brighenti E; Govoni M; Imbrogno E; Fornari F; Treré D; Montanaro L; Derenzini M
Oncogene; 2016 Feb; 35(8):977-89. PubMed ID: 25961931
[TBL] [Abstract][Full Text] [Related]
45. Ribosome biogenesis may augment resistance training-induced myofiber hypertrophy and is required for myotube growth in vitro.
Stec MJ; Kelly NA; Many GM; Windham ST; Tuggle SC; Bamman MM
Am J Physiol Endocrinol Metab; 2016 Apr; 310(8):E652-E661. PubMed ID: 26860985
[TBL] [Abstract][Full Text] [Related]
46. The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.
Pignochino Y; Dell'Aglio C; Inghilleri S; Zorzetto M; Basiricò M; Capozzi F; Canta M; Piloni D; Cemmi F; Sangiolo D; Gammaitoni L; Soster M; Marchiò S; Pozzi E; Morbini P; Luisetti M; Aglietta M; Grignani G; Stella GM
BMC Cancer; 2015 May; 15():374. PubMed ID: 25952930
[TBL] [Abstract][Full Text] [Related]
47. Attacking c-Myc: targeted and combined therapies for cancer.
Huang H; Weng H; Zhou H; Qu L
Curr Pharm Des; 2014; 20(42):6543-54. PubMed ID: 25341931
[TBL] [Abstract][Full Text] [Related]
48. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P
Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193
[TBL] [Abstract][Full Text] [Related]
49. Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice.
Galindo-Campos MA; Lutfi N; Bonnin S; Martínez C; Velasco-Hernandez T; García-Hernández V; Martín-Caballero J; Ampurdanés C; Gimeno R; Colomo L; Roué G; Guilbaud G; Dantzer F; Navarro P; Murga M; Fernández-Capetillo O; Bigas A; Menéndez P; Sale JE; Yélamos J
Blood; 2022 Jan; 139(2):228-239. PubMed ID: 34359075
[TBL] [Abstract][Full Text] [Related]
50. Signal Transduction in Ribosome Biogenesis: A Recipe to Avoid Disaster.
Piazzi M; Bavelloni A; Gallo A; Faenza I; Blalock WL
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31163577
[TBL] [Abstract][Full Text] [Related]
51. MYC as a regulator of ribosome biogenesis and protein synthesis.
van Riggelen J; Yetil A; Felsher DW
Nat Rev Cancer; 2010 Apr; 10(4):301-9. PubMed ID: 20332779
[TBL] [Abstract][Full Text] [Related]
52. Ribosomal proteins L5 and L11 co-operatively inactivate c-Myc via RNA-induced silencing complex.
Liao JM; Zhou X; Gatignol A; Lu H
Oncogene; 2014 Oct; 33(41):4916-23. PubMed ID: 24141778
[TBL] [Abstract][Full Text] [Related]
53. CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy.
Siddiqui-Jain A; Bliesath J; Macalino D; Omori M; Huser N; Streiner N; Ho CB; Anderes K; Proffitt C; O'Brien SE; Lim JK; Von Hoff DD; Ryckman DM; Rice WG; Drygin D
Mol Cancer Ther; 2012 Apr; 11(4):994-1005. PubMed ID: 22267551
[TBL] [Abstract][Full Text] [Related]
54. Translation Stress Regulates Ribosome Synthesis and Cell Proliferation.
Vadivel Gnanasundram S; Fåhraeus R
Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30486342
[TBL] [Abstract][Full Text] [Related]
55. Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis.
Keller UB; Old JB; Dorsey FC; Nilsson JA; Nilsson L; MacLean KH; Chung L; Yang C; Spruck C; Boyd K; Reed SI; Cleveland JL
EMBO J; 2007 May; 26(10):2562-74. PubMed ID: 17464290
[TBL] [Abstract][Full Text] [Related]
56. MYC deregulation in lymphoid tumors: molecular mechanisms, clinical consequences and therapeutic implications.
Sewastianik T; Prochorec-Sobieszek M; Chapuy B; Juszczyński P
Biochim Biophys Acta; 2014 Dec; 1846(2):457-67. PubMed ID: 25199984
[TBL] [Abstract][Full Text] [Related]
57. Genetic and epigenetic regulation of skeletal muscle ribosome biogenesis with exercise.
Figueiredo VC; Wen Y; Alkner B; Fernandez-Gonzalo R; Norrbom J; Vechetti IJ; Valentino T; Mobley CB; Zentner GE; Peterson CA; McCarthy JJ; Murach KA; von Walden F
J Physiol; 2021 Jul; 599(13):3363-3384. PubMed ID: 33913170
[TBL] [Abstract][Full Text] [Related]
58. c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription.
Arabi A; Wu S; Ridderstråle K; Bierhoff H; Shiue C; Fatyol K; Fahlén S; Hydbring P; Söderberg O; Grummt I; Larsson LG; Wright AP
Nat Cell Biol; 2005 Mar; 7(3):303-10. PubMed ID: 15723053
[TBL] [Abstract][Full Text] [Related]
59. Induction of apoptosis in Eμ-myc lymphoma cells in vitro and in vivo through calpain inhibition.
Li H; Nepal RM; Martin A; Berger SA
Exp Hematol; 2012 Jul; 40(7):548-563.e2. PubMed ID: 22366408
[TBL] [Abstract][Full Text] [Related]
60. Inauhzin(c) inactivates c-Myc independently of p53.
Jung JH; Liao JM; Zhang Q; Zeng S; Nguyen D; Hao Q; Zhou X; Cao B; Kim SH; Lu H
Cancer Biol Ther; 2015; 16(3):412-9. PubMed ID: 25692307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
